The Impact of Olanzapine on Tardive Dyskinetic Symptoms in a State Hospital Population

References

• Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry. 2000;61:10–14.
   Google Scholar
• Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry. 2000;61:21–26.
   Google Scholar
• Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry. 2000;61:15–20.
   Google Scholar
• Woerner MG, Saltz BL, Kane JM, Lieberman JA, Alvir JM: Diabetes and development of tardive dyskinesia. Am J Psychiatry. 1993;150:966–968.
   Google Scholar
• Kane JM, Smith JM. Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39:473–481.
   Google Scholar
• Woerner MG, Kane JM, Lieberman JA, Alvir J, Bergmann KJ, Borenstein M, Schooler NR, Mukherjee S, Rotrosen J, Rubinstein M. The prevalence of tardive dyskinesia. J Clin Psychopharma-col. 1991;11:34–42.
   Google Scholar
• Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: Prevalence and incidence. J Clin Psychiatry. 2004;65:16–20.
   Google Scholar
• Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res. 1999;35:S61–S66.
   Google Scholar
• Cole JO, Gardos G, Tarsy D. Drug trials in persistent dyskinesia. In: Fann WE, Smith RC, Davis JM, eds. Tardive Dyskinesia Research, and Treatment. New York: SP Medical and Scientific Books; 1980:419–427.
   Google Scholar
• Gerbino L, Shopsin B, Collora M. Clozapine in the treatment of tardive dyskinesia: An interim report. In: Fann WE, Smith RC, Davis JM, eds. Tardive Dyskinesia Research, and Treatment. New York: SP Medical and Scientific Books; 1980:475–489.
   Google Scholar
• Small JG, Milstein V, Marhenke JD, Hall DD, Kellams JJ. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry. 1987;48:263–267.
   Google Scholar
• Lieberman JA, Saltz BL, Johns CA, Pollack S, Kane JM. Clozapine effects on tardive dyskinesia. Psychopharmacol Bull. 1989;25:57–62.
   Google Scholar
• Levin H, Chengappa KN, Kambhampati RK, Mahdavi N, Ganguli R. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients? J Clin Psychiatry. 1992;53:248–251.
   Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies [see comment]. Am J Psychiatry. 2004;161: 414–425.
   Google Scholar
• Almeida OP. Olanzapine for the treatment of tardive dyskinesia. J Clin Psychiatry. 1998;59:380–381.
   Google Scholar
• Littrell KH, Johnson CG, Littrell S, Peabody CD. Marked reduction of tardive dyskinesia with olanzapine. Arch Gen Psychiatry. 1998;55:279–280.
   Google Scholar
• Agarwal V, Kumar P. Olanzapine in the treatment of tardive dys-kinesia: A report of 2 cases. J Clin Psychiatry. 2001;62:298–299.
   Google Scholar
• Raja M, Azzoni A, Maisto G. Three cases of improvement of tar-dive dyskinesia following olanzapine treatment. Int J Neuropsy-chopharmacol. 1999;2:333–334.
   Google Scholar
• Lykouras L, Agelopoulos E, Tzavellas E. Improvement of tardive dyskinesia following switch from neuroleptics to olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:815–817.
   Google Scholar
• Snoddgrass PL, Labbate LA. Tardive dyskinesia from risperidone and olanzapine in an alcoholic man. Can J Psychiatry. 1999;44:921.
   Google Scholar
• Strous RD, Kupchik M, Roitman S, Schwartz S, Gonen N, Mester R, Weizman A, Spivak B. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. Hum Psychopharmacology. 2006;21:235–243.
   Google Scholar
• Herran A, Vazquez-Barquero JL. Tardive dyskinesia associated with olanzapine. Ann Intern Med. 1999;131:72.
   Google Scholar
• Bella VL, Piccoli F. Olanzepine-induced tardive dyskinesia. Br J Psychiatry. 2003;182:81–82.
   Google Scholar
• Bhanji NH, Margolese HC. Tardive dyskinesia associated with olanzapine in a neuroleptic-naive patient with schizophrenia. Can J Psychiatry. 2004;49:343.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: Department of Health and Human Services; 1976.
   Google Scholar
• Schooler NR, Kane JM. Research diagnoses for tardive dyskine-sia. Arch Gen Psychiatry. 1982;39:486–487.
   Google Scholar
• Levine J, Chengappa KNR, Patel M, Vagnucci A, John V, Brar JS, Chalasani L, Parepally H, Ganguli R. Obesity and medical illnesses in psychiatric patients admitted to a long-term psychiatric facility. J Psych Pract. 2001;11:432–439.
   Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158:360–369.
   Google Scholar
• Sakai K, Gao XM, Hashimoto T, Tamminga CA. Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Synapse. 2001;39:152–160.
   Google Scholar
• Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, Renshaw PF. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry. 2002;51:493–497.
   Google Scholar
• Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 2002;26:325–339.
   Google Scholar
• Li XM, Chlan-Fourney J, Juorio AV, Bennett VL, Shrikhande S, Keegan DL, Qi J, Boulton AA. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. J Neurosci Res. 1999;56:72–75.
   Google Scholar
• de Jesus Mari J, Lima MS, Costa AN, Alexandrino N, Rodrigues-Filho S, de Oliveira IR, Tollefson GD. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. Eur Arch Psychiatry Clin Neurosci. 2004;254:356–361.
   Google Scholar
• Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: A prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:985–996.
   Google Scholar
• Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF. Long-term olanzapine therapy in the treatment of bipolar I disorder: An open-label continuation phase study. J Clin Psychiatry. 2001;62:273–281.
   Google Scholar